Mesoblast Limited (MESO, MSB.AX) said that the U.S. Food and Drug Administration has granted its second generation allogeneic, ...

FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), ...

Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially ...

A North American multicenter retrospective cohort study was conducted by the Alliance for Adult Research in Congenital Cardiology on individuals with a uRV and ... or thromboembolic events was ...

Fetal Congenital Heart Disease,Fetal Heart Rate,Fetal Movements,Global Average Pooling,Global Representation,Hypoplastic Left Heart Syndrome,Left Ventricular,Left Ventricular Outflow Tract,Local ...

Mesoblast Ltd (ASX: MSB) shares are under pressure today despite some big news. What's going on with this share?

Elucidating the roles of SLC25A1 and PSG1 would open pathways to novel preventive treatments for congenital heart defects linked with abnormalities of the placenta.

Researchers have found new genes that contribute to hypoplastic left heart syndrome (HLHS), a rare, life-threatening heart disease that occurs in infants.

Anyone who's healed from a cut or a scrape has witnessed the incredible regenerative power of stem cells. These cells can create identical copies of ...

A 25-year-old born with hypoplastic left heart syndrome is aiming to improve the experiences of hospital patients across the ...

Ayden Skillman of Greybull was born without a complete heart and has spent much of his young life in hospitals. Now the ...

Newborn screening, conducted within the first 24-48 hours post-birth, identifies hidden genetic, metabolic, and endocrine ...